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Abstract 
Background: Exogenous oxytocin was approved by the FDA in 1962 and has been administered to help 
induce labor, advance a prolonged labor, assist with placental delivery, and manage postpartum bleeding. 
However, the use of this synthetic oxytocin is commonly both inconsistent and incautious in timing and 
dosing, with outcomes of uterine tachysystole (hyperstimulation), subsequent fetal oxygen desaturation 
and alterations in fetal heart rate patterns, all potentially leading to emergency cesarean sections (CS). 
Since such associations have been established, would the implementation of a guideline-based approach 
on the precautious use of synthetic oxytocin in labor augmentation reduce emergency CS rates? 
Methods: An exhaustive literature search was performed using MEDLINE-PubMed, CINAHL, Proquest, and 
Web of Science databases. Key terms searched include oxytocin, intervention, fetal distress, reduc*, 
obstetric labor complications, education, guidelines as topic, protocol, and checklist. Articles that 
included a guideline approach to using oxytocin in labor augmentation and reported on emergency CS 
rates were included. Exclusion criteria included guidelines based on the third stage of labor. The 
remaining articles and their references were screened for eligibility, were critically appraised, and the 
quality of their evidence was assessed with the GRADE working group approach. 
Results: Four studies met the inclusion and exclusion criteria and were eligible to be included in this 
systematic review. All were observational studies, 2 prospective and 2 retrospective. One study reported a 
significant reduction in the frequency of oxytocin use and a significant increase in overall emergency CS, 
but also a significant increase in oxytocin used in labors without dystocia. A second study found a 
significant reduction in the frequency of oxytocin use, emergency CS overall, and emergency CS indicated 
for fetal distress with a non-significant decrease in CS due labor dystocia. A third study reported a 
statistically significant reduction in the maximum oxytocin dose, with a non-significant decrease in CS 
rate post-checklist. The fourth study found a statistically significant reduction in the frequency of oxytocin 
use, a non-significant decrease in CS rate, a statistically significant increase in CS due to labor dystocia 
with a statistically significant reduction in those due to fetal distress. All studies were assessed as very 
low quality of evidence based on GRADE. 
Conclusion: The studies collectively demonstrate that a guideline-based approach on the precautious use 
of synthetic oxytocin during labor management leads to a reduced frequency of its use and/or a decrease 
in the maximum dose. However, the impact on emergency CS rates became a moving target as each 
study used different guidelines. This reveals the necessity of a standardized approach that includes a 
universal definition of labor dystocia and a protocol that guides when to start, continue, or stop oxytocin. 
This could be accomplished by a future study that assessed a dose response curve to evaluate if a low or 
high dose oxytocin regimen, in combination with a universal guideline with provided markers for when to 
initiate and stop synthetic oxytocin, would correlate to a decline in emergent CS rates. 
Keywords: oxytocin, intervention, fetal distress, reduc*, obstetric labor complications, education, 
guidelines as topic, protocol, and checklist. 
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Abstract   
 
Background: Exogenous oxytocin was approved by the FDA in 1962 and has been 
administered to help induce labor, advance a prolonged labor, assist with placental 
delivery, and manage postpartum bleeding. However, the use of this synthetic oxytocin 
is commonly both inconsistent and incautious in timing and dosing, with outcomes of 
uterine tachysystole (hyperstimulation), subsequent fetal oxygen desaturation and 
alterations in fetal heart rate patterns, all potentially leading to emergency cesarean 
sections (CS). Since such associations have been established, would the implementation 
of a guideline-based approach on the precautious use of synthetic oxytocin in labor 
augmentation reduce emergency CS rates?  
 
Methods: An exhaustive literature search was performed using MEDLINE-PubMed, 
CINAHL, Proquest, and Web of Science databases. Key terms searched include oxytocin, 
intervention, fetal distress, reduc*, obstetric labor complications, education, guidelines 
as topic, protocol, and checklist. Articles that included a guideline approach to using 
oxytocin in labor augmentation and reported on emergency CS rates were included. 
Exclusion criteria included guidelines based on the third stage of labor. The remaining 
articles and their references were screened for eligibility, were critically appraised, and 
the quality of their evidence was assessed with the GRADE working group approach.  
 
Results: Four studies met the inclusion and exclusion criteria and were eligible to be 
included in this systematic review. All were observational studies, 2 prospective and 2 
retrospective.  One study reported a significant reduction in the frequency of oxytocin 
use and a significant increase in overall emergency CS, but also a significant increase in 
oxytocin used in labors without dystocia. A second study found a significant reduction in 
the frequency of oxytocin use, emergency CS overall, and emergency CS indicated for 
fetal distress with a non-significant decrease in CS due labor dystocia. A third study 
reported a statistically significant reduction in the maximum oxytocin dose, with a non-
significant decrease in CS rate post-checklist. The fourth study found a statistically 
significant reduction in the frequency of oxytocin use, a non-significant decrease in CS 
rate, a statistically significant increase in CS due to labor dystocia with a statistically 
significant reduction in those due to fetal distress. All studies were assessed as very low 
quality of evidence based on GRADE.  
 
Conclusion: The studies collectively demonstrate that a guideline-based approach on 
the precautious use of synthetic oxytocin during labor management leads to a reduced 
frequency of its use and/or a decrease in the maximum dose. However, the impact on 
emergency CS rates became a moving target as each study used different guidelines. 
This reveals the necessity of a standardized approach that includes a universal definition 
of labor dystocia and a protocol that guides when to start, continue, or stop oxytocin. 
This could be accomplished by a future study that assessed a dose response curve to 
evaluate if a low or high dose oxytocin regimen, in combination with a universal 
guideline with provided markers for when to initiate and stop synthetic oxytocin, would 
correlate to a decline in emergent CS rates.  
 
Keywords: oxytocin, intervention, fetal distress, reduc*, obstetric labor 
complications, education, guidelines as topic, protocol, and checklist. 
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Guideline-Based Approach for the Precautious Use          
of Oxytocin in Labor Augmentation and                   
Emergency Cesarean Section Rates 
 
 
BACKGROUND 
 Oxytocin is an endogenous hormone that is produced by the hypothalamus and 
stored in the pituitary gland. It is naturally released from the posterior lobe of the 
pituitary gland during spontaneous labor and stimulates uterine smooth muscle 
contractions. Synthetic oxytocin is an exogenous form of oxytocin that increases the rate 
and amplitude of labor contractions, and, like any contraction, also momentarily 
obstructs blood flow to the uterus. This exogenous source of oxytocin is frequently used 
to augment labor, as it was approved by the FDA in 1962 to precipitate physiologically 
analogous contractions.1 Specifically, it is indicated to induce labor, advance a prolonged 
labor (labor dystocia), assist with the delivery of the placenta (third stage of labor), and 
manage postpartum bleeding.2 
The many indications of synthetic oxytocin leaves room for subjective 
interpretation and currently there is no clear consensus on when to initiate oxytocin nor 
how much to administer in both the induction of labor and augmentation of a 
spontaneous labor. This review will focus on those 2 areas of labor, the induction of 
labor and the augmentation of the first or second stages of labor. Even with this 
emphasis, there are still low-dose and high-dose regimens that vary in the initial dose as 
well as in titration schedules, and, when given, synthetic oxytocin is usually “dosed to 
effect” meaning until a particular uterine contraction pattern is reached.2 Not 
surprisingly, inconsistent and unnecessary use of synthetic oxytocin is common.3 This is 
concerning, as oxytocin administration has been associated with uterine tachysystole 
(hyperstimulation)2,4 and subsequent fetal oxygen desaturation and alterations in fetal 
heart rate patterns5 which potentially leads to emergency cesarean sections (CS).6 
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Hyperstimulation and tachysystole of the uterus reduces the time between the end of a 
contraction and the start of another, also known as relaxation time. One study7 
evaluated umbilical artery pH in relation to contraction characteristics during the first 
stage of labor, and found that umbilical artery acidosis was significantly associated with 
contractions that were longer in duration, increased in amplitude, frequency, and 
pressure, and subsequently a shorter relaxation time. The concern lies here.  
Furthermore, due to synthetic oxytocin’s potential to cause “significant patient 
harm” when used inappropriately,2,4 it is now considered a “high alert medication” by the 
Institute for Safe Medication Practices.8 They also require both maternal and fetal 
monitoring while the synthetic oxytocin is being administered.1,9 Since such associations 
have been established, would the implementation of a guideline-based approach on the 
precautious use of synthetic oxytocin in labor augmentation reduce emergency CS rates?  
 
METHODS 
An initial search of medical literature was performed using MEDLINE-PubMed, 
CINAHL, Proquest, and Web of Science. Key terms searched include “oxytocin,” 
“intervention,” “fetal distress,” and “reduc*.” An additional search was then conducted 
using the PubMed search engine with the keywords “obstetric labor complications,” 
“education,” “guidelines as topic,” “protocol,” and “checklist.”  References were screened 
for eligibility. Articles that included a guideline approach to using synthetic oxytocin in 
labor augmentation and reported on emergency CS rates were included. Exclusion 
criteria included guidelines based on the third stage of labor or post-partum 
hemorrhage, and articles not published in English language. The quality of evidence was 
assessed with the GRADE working group approach.10  
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RESULTS 
The initial search yielded 55 studies and the supplementary search yielded 90 
articles for a total of 145 articles. Duplicates were removed, the remaining articles were 
reviewed for eligibility criteria, and 3 articles remained. The 3 article’s bibliographies 
were then screened for eligibility criteria, leading to a total of 4 observational 
studies.9,11,13,14 
 
Gaudernack et al 
This prospective observational intervention study9  implemented both a guideline 
and an educational program on the mindful use of oxytocin during labor in at-term, first 
time mothers at a Norwegian University Hospital. They collected patient data from 
electronic records pre-guideline, from October 2012 to May 2013, and then again post-
guideline, from April 2014 to April 2015. The authors noted that the post-guideline data 
period was purposefully extended as “effect of quality improvement interventions is 
known to diminish with time.”9  The authors specifically focused on this population due 
to a recent report3 showing an increase and imprudent use of oxytocin, specifically in 
primiparous women. Their guidelines recommended that oxytocin only be used in the 
setting of labor dystocia, and the authors hypothesized that this intervention would lead 
to an overall reduction in oxytocin administration and, when given, would exclusively be 
to women with the diagnosis of labor dystocia.9 
The hospital used the Proactive Labor Support definition of dystocia pre-
intervention, which specified that labor began at 1cm cervical dilation with effacement 
and painful, regular contractions, and that dystocia occurred when dilation progressed 
less than 1cm/hr. Post-intervention, dystocia was diagnosed when there was 2 hours of 
labor without progress. However, the new guidelines did not change the definition of the 
start of labor and did not modify oxytocin augmentation during the second stage of 
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labor. The study also incorporated an educational component, where the midwives 
participated in a course that reviewed the new guidelines and the positives and 
negatives of oxytocin therapy. A  “project leader” then gave a lecture to both the 
midwives and doctors.9 
 The study included primiparous women with spontaneous labor onset and whose 
patient data included dystocia information. They excluded women with induced labors. 
The pre-intervention cohort included 431 women and the post-intervention cohort 
included 664 women. Post-intervention, there was a significant increase in overall 
emergency CS (6.7% vs. 10.2%; p<0.05) but with no significant change in dystocia or 
asphyxia as indications for CS. As hypothesized, they reported a significant reduction in 
frequency of oxytocin used (63.3% vs. 54.1%; p<0.001) and in woman diagnosed with 
dystocia (68.9% vs. 52.9%; p<0.001). Interestingly, oxytocin was administered in 
significantly more labors without dystocia (8.4% vs. 18.9%; p<0.001), falling under the 
category of oxytocin given without indication, the very concept that they were trying to 
improve.9 
The authors argued that the increase in CS rates was most likely due to other 
variables and explored the idea that their definitions on the start of labor and dystocia 
may have been too strict and prevented labor to progress at a slower rate without 
augmentation.9  
 
Rossen et al 
This prospective observational study11 implemented a guideline on the “judicious” 
use of oxytocin in labor augmentation at the Stavanger University Hospital in Norway. 
The study included 10 overall groups but listed 4 specific: nulliparous, single, cephalic 
presentation, >37 weeks in spontaneous labor (group 1), nulliparous, single, cephalic 
presentation, >37 weeks induced before labor (group 2a), multiparous (excluding 
previous CS), single, cephalic presentation, >37 weeks in spontaneous labor (group 3), 
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multiparous (excluding previous CS), single, cephalic presentation, >37 weeks induced 
before labor (group 4a). The study collected data from an electronic birth journal from 
January 2009 to December 2013, with the implementation of the guideline occurring in 
January 2010.11 
Their guideline restricted the use of oxytocin to patients with the diagnosis of 
labor dystocia in both nulliparous and multiparous women, during the first stage of labor 
of spontaneous onset (groups 1 and 3), or before the start of the active phase in the 
setting of induced labors and/or after dystocia in the first stage of labor after induction 
(groups 2a and 4a). Oxytocin was administered until contractions reached a rate of 3-5 
every 10 minutes. Pre-guideline, the beginning of labor was defined by regular and 
painful contractions and the active phase of labor definition used was by The World 
Health Organization (WHO) of cervical dilation of 4cm with cervical effacement. There 
was no definition to diagnose dystocia and instead oxytocin was used subjectively by 
individual physicians and midwives. Post-guideline, the 2014 WHO definition of 
dystocia12 was employed, which delineated a prolonged labor as 4 hours without cervical 
dilation progress once the active phase of labor is reached. However, their guideline did 
not alter oxytocin use in the second or third stages of labor.11  
The pre-guideline cohort included 3926 patients and the post-guideline cohort 
included 16 301 patients for a total of 20 227. Group 1 comprised 28.6%, group 2a was 
8.9%, group 3 was 37.2%, and group 4a was 9.2%. Post-guideline, they found a 
significant decrease in both emergency CS overall (6.9% vs. 5.3%; p<0.05) and overall 
emergency CS indicated for fetal distress (3.2% vs. 2.0%; p<0.01). In subgroup 
analysis, statistical significance was reached for emergency CS due to fetal distress in 
groups 1 and 2a only. Interestingly, the frequency of prolonged labor leading to 
emergency CS did not change significantly (2.2% vs. 1.7%; p=0.75). As hypothesized, 
there was a significant reduction in the frequency of oxytocin use in labor augmentations 
across all groups (all p<0.01).11 
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The authors concluded that the observed reduction in oxytocin administration 
correlated to the reduction of overall emergency CS rates and cases of fetal distress 
leading to emergency CS.11 
 
Clark et al  
This retrospective observational study13 applied a detailed checklist-based 
protocol on the use of oxytocin in labor augmentation of women with at term, vertex 
position, and singleton pregnancies without a history of CS across the Hospital 
Corporation of America health care system. The Hospital Corporation of America system 
includes physicians, pharmacists, nurses, and consultants in 125 obstetrics and 
gynecology departments across 20 states. The study initially reviewed 100 charts 
specifically from St. Mark’s Hospital in Salt Lake City, Utah both before and after the 
implementation of the checklist-based protocol on March 1, 2005. After this, data was 
analyzed and the checklist-based protocol was then employed across the Hospital 
Corporation of America system.13 
The protocol included 2 checklists, including a pre-oxytocin checklist and an “in 
use” oxytocin checklist. The pre-oxytocin checklist was required to be completed before 
the start of oxytocin therapy and included specifications such as “pelvis is documented 
by physician to be clinically adequate,” “status of the cervix is assessed,” “presentation 
is assessed,” “indication for induction,” and “fetal assessment completed,” among 
others. When oxytocin had already been started, a subsequent checklist was to be 
completed every 30 minutes. If the checklist could not be completed, oxytocin was 
recommended to be either decreased or stopped. This second checklist focused on fetal 
assessment regarding the number of accelerations and decelerations, as well as a 
uterine contraction review on the rate, duration, palpation, and pressure. The authors 
note that their protocol was “purposefully far more conservative than would be required 
by current standards of care” but felt it was necessary since oxytocin is “the drug most 
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commonly implicated in avoidable medication related adverse outcomes.”13 This being 
said, the protocol focused overall on fetal and uterine contraction response but allowed 
both low and high dose regimens.13 
The piloted study at St. Mark’s Hospital found no change in the rate of CS and a 
significant decrease in the maximum dose of oxytocin in the checklist managed group. 
When the study was then employed across the system, the first year data on 220 000 
deliveries found a decrease in CS rates (23.6% vs. 21.0%), a change from previously 
reported annual increases (1-4%) in CS rates in years prior. Intriguingly, such stringent 
guidelines might be forecasted to increase the rate of CS, not a system wide decrease as 
this study observed. The authors argued that this is most likely related to the overall 
reduction in maximum oxytocin dose post-checklist (17% decrease; p<0.003) leading to 
less uterine hyperstimulation, as this adverse event is dose-related.13  
This study implemented a stringent protocol for the use of oxytocin but permitted 
medical providers to administer oxytocin across the range of acceptable dosing regimens 
without judgement. This allowed for the guideline-based approach to be assessed on its 
own, as a foundation to reaching the goal of using oxytocin in a conservative, evidenced 
based manner.     
 
Rohn et al 
This retrospective observational study14 implemented a low-dose, checklist-based 
oxytocin protocol in an urban tertiary care center. The study collected data from 
delivering women with singleton pregnancies using electronic medical records. They 
included data from 4370 deliveries 15 months prior to the implementation of the 
protocol in July 2009, then allowed for a 9-month wash-out period after the initiation of 
the guideline, and then included data from 4347 deliveries for the 15 months following. 
The total study period was between January 1, 2008 and March 31, 2011. Notably, 
women who delivered between April 1, 2009 and December 31, 2009 were not included 
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in the study to allow for both a transition period and to minimize seasonal or monthly 
confounding variables.14 
The protocol included 1 dosing regimen with a specified maximum dose rate, for 
2 checklists. The first checklist was to be completed before oxytocin could be used for 
labor induction or labor augmentation, and included the same specifications as Clark et 
al13  such as “pelvis is documented by physician to be clinically adequate,” “status of the 
cervix is assessed,” “presentation is assessed,” “indication for induction,” and “fetal 
assessment completed.” Similarly, the second checklist was completed every 30 minutes 
after to determine if oxytocin could be continued and focused on a fetal assessment 
regarding the number of accelerations and decelerations, as well as a uterine contraction 
review on the rate, duration, palpation, and pressure. Dissimilar to Clark et al,13 the 
second checklist also specified the dosing rate of oxytocin titration.14 
The study found a non-significant decrease in overall emergency CS rates (662 
women vs. 641 women; p=0.6) as well as emergency CS rates in deliveries augmented 
with oxytocin post-checklist (484 women vs. 463 women; p=0.28). They also reported 
an overall statistically significant increase in emergency CS due to labor dystocia (40.9% 
vs. 50.6%; p<0.001) and in women who received oxytocin (44.8% vs. 57.5%; 
p<0.001), but a statistically significant decrease in overall emergency CS due to fetal 
distress (38.7% vs. 32.5%; p=0.02) and in women who received oxytocin (42.0% vs. 
27.4%; p<0.001) post-checklist. There were no significant changes observed for women 
who did not receive oxytocin for rates of emergency CS for dystocia nor fetal distress. 
Additionally, they found both a significant reduction in the frequency of oxytocin use 
(61.2% vs. 55.3%; p<0.001) and in the maximum dose administered (11 mU/min vs. 
10 mU/min; p<0.001) post-checklist.14 
This study was distinctive in that it used a similar protocol already assessed by a 
previous study.13 However, it altered 2 variables concurrently by adding a low dose 
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regimen to a new checklist-based protocol, and then drew conclusions on individual 
obstetric outcomes.  
 
DISCUSSION 
Collectively, these 4 studies9,11,13,14 demonstrate that a guideline-based approach 
regarding the precautious use of synthetic oxytocin during labor management leads to a 
reduced frequency of its use and/or a decrease in the maximum dose. However, the 
impact on emergency CS rates became a moving target. This is unsurprising when one 
considers the variability in each study’s justification of when and how to implement 
oxytocin. Gauderneck et al9 and Rossen et al11 both used "labor dystocia” as the basis for 
initiating oxytocin, but then they used 2 different definitions of labor dystocia. 
Gauderneck et al9 diagnosed labor dystocia when there was 2 hours of labor observed 
without progress, while Rossen et al11 diagnosed labor dystocia when there was 4 hours 
of labor without cervical dilation progress once the women was in the active phase of 
labor. Furthermore, the Clark et al13 and Rohn et al14 studies did not base their protocols 
off of labor dystocia and instead used various measures on both maternal and fetal 
status. The 2 studies13,14 used near-identical checklist protocols, which went a step 
further than Gauderneck et al9 and Rossen et al11 by including not only a guide for when 
to initiate oxytocin, but also used a checklist for the continuation of oxytocin 
augmentation. However, Rohn et al14 differs from all 3 other studies in that they also 
implemented a new low-dose regimen in conjunction with the new guideline-based 
protocol.  
Due to the focus of this review, a noteworthy study15 considers the outcome of 
CS to be overly broad and the CS rate to be “arbitrary” and no longer a concern due to 
the safety of the surgery today. Unfortunately, this tolerance of the rate of CS does not 
fully consider the safety of CS globally. The World Health Organization (WHO)12 
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considers the high, increasing CS rate worldwide a substantial issue and recently 
released a new guideline16 on the reduction of unnecessary CS. Alongside this, the WHO 
places a high priority on the safety of labor and delivery and on a woman’s “autonomy”12 
during that process. A woman’s autonomy during her labor is stifled when maternal and 
fetal monitoring is required during synthetic oxytocin therapy1,9 and it is removed 
completely when surgery becomes the emergent, life-saving option. Since there is a 
high frequency of labors currently augmented with oxytocin in developed countries, the 
research and outcomes considered, which eventually lead to the protocols executed, 
impact high-income countries and low-income countries alike.12 As synthetic oxytocin 
becomes more accessible, these low-income developing countries that operate in low 
resource settings will be looking to both local and global protocols for how to safely and 
effectively induce and augment labor. Partly in response to the WHO guideline, The 
Lancet also recently released a 3 paper series17-19 on the optimization of CS globally. The 
series addressed the inequalities surrounding the use of CS,17 evaluated the short and 
long term health effects of CS in mothers and their children,18 and discussed approaches 
for the reduction of unnecessary CS.19 A CS is a surgical procedure involving not just 1 
but 2 individuals and therefore should require forethought. Overall, the outcome of the 
rate of CS is far from “arbitrary.” 
The 4 reviewed studies9,11,13,14 agree that the current approach to oxytocin use is 
too variable, lacks an evidence based regimen, leads to inappropriate use, and also to 
unwanted obstetric and fetal outcomes. Yet their guidelines vary so much that, when 
considered together, the confounding variables cannot fully be teased out from synthetic 
oxytocin’s effect on emergency CS rates. 
In addition, the studies9,11,13,14 are all observational cohort studies and so the 
conclusions made are indirect correlations since they assume that the reduction in 
oxytocin use and/or a reduction in the maximum dosage is related to the change in 
emergency CS rates observed. Gaudernack et al9 assumes that the reduction in labors 
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augmented with oxytocin post-guideline correlates to the increased emergency CS rate. 
However, they provide insufficient explanation for supplementary findings. They 
reported a decrease in woman diagnosed with dystocia, but then a significant increase in 
labors augmented with oxytocin in patients without labor dystocia diagnosed, and also 
reported no significant changes in the number of emergency CS due to dystocia or 
asphyxia. The study’s departing thought of their observed increase in emergency CS 
rates was most likely due to other variables is not explicit enough for an outcome such 
as emergency CS. The strength of this study is that they did specifically include an 
educational program as part of their protocol.  
Rossen et al11 also assumes that the reduction in labors augmented with oxytocin 
post-guideline correlates to the reduced emergency CS rate. One strength is that they 
included 20 227 labors and did subgroup analysis of their outcomes using combinations 
of nulliparous and multiparous women experiencing induction of labor and/or active 
labor augmentation with oxytocin.  
Clark et al13 makes the assumption that a checklist-based approach to starting, 
continuing, and/or stopping oxytocin correlated with decreased emergency CS. Notably, 
the study permitted the current range of low and high dose oxytocin regimens as long as 
the checklists could be completed. Precision is low for the results from the initial 
segment of the study where they piloted the checklist protocol in 1 hospital and only 
reviewed 200 charts in total. However, the true strength of this study is that they then 
extended the checklist-based protocol across an entire health system, reaching 125 
departments in 20 states and reviewing charts on 220 000 deliveries.  
Lastly, Rohn et al14 used a near identical checklist-based approach as the one 
assessed in Clark et al13 but with an additional requirement of a low-dose oxytocin 
regimen. However appealing, they created a confounding variable without having a high-
dose oxytocin regimen to compare outcomes to. The study14 also made the assumption 
that the checklist approach to starting, continuing, and/or stopping oxytocin with a low-
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dose regimen correlated with the non-significant decrease in emergency CS rates. 
Additionally, it did not exclude women with a prior CS history, which is not only a 
separate topic up for debate but significantly separates their study population from the 
other 3 studies9,11,13 that specified a history of prior CS as exclusion criteria. 
Unfortunately, the authors did not address this point directly nor speak to the potential 
adverse outcomes.  
 The very low quality of evidence of these studies as assessed by the GRADE 
working group10 makes the process of delivering a definite conclusion difficult. Better 
studies might include a dose response curve assessment, comparing a low-dose vs. a 
high-dose regimen, with a universal protocol that provides markers for when to initiate, 
continue, or stop oxytocin therapy. The protocol aspect allows for shift workers, 
including nurses, midwives, and medical providers, all with a range of experience, to 
understand and pick up where the last medical professional left off without any 
confusion. This might relieve any pressure felt to “hurry along” a naturally progressing 
labor for the benefit of a work schedule.13 Additionally, a low-dose vs. high-dose 
oxytocin regimen comparison will assess the current notion of administering oxytocin in 
the manner of a titration to effect.2 This method would also address the effect of the 
dose on uterine tachysystole (hyperstimulation),2,4 subsequent fetal oxygen 
desaturation, and alterations in fetal heart rate patterns5 potentially leading to 
emergency CS.6  
Understandably, there are great risks involved when we consider meddling with 
outcomes of maternal and fetal health. This is precisely why guidelines based on safety 
and evidence are more than appropriate.  
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CONCLUSION 
Current use of synthetic oxytocin during labor augmentation is unstructured and 
irregular in both the range of dosing and its indications, often times leading to 
unnecessary administration.3 Excessive use has been implicated as a means for an 
expedited birth for both the provider and the patient.15 However innocent the intent, 
synthetic oxytocin is very commonly cited in preventable, medication associated 
negative side effects.13,15 Errors such as these can lead to patient harm and be a 
professional liability to the healthcare provider and the institution.4 Best medical practice 
is prioritizing patient safety and applying evidence based care, therefore a standardized 
approach regarding labor augmentation with oxytocin, including a universal definition of 
labor dystocia and guidelines for when to initiate, stop, or continue oxytocin therapy is 
essential. 
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TABLES 
 
 
 
 
 
Table 1: Quality Assessment of Reviewed Articles 
 
Study Design 
Downgrade Criteria 
Upgrade Criteria Quality 
Limitations Indirectness Inconsistency Imprecision Publication bias 
Gaudernack et al9 Cohort  Not Serious  Seriousa Seriousb Not Serious  Unlikely   None  Very low 
Rossen et al11 
 
Cohort Not Serious Seriousa Not Serious  Not Serious  Unlikely   None Very low  
Clark et al13 Cohort  Not Serious Seriousa,c Not Serious  Not Seriousd Unlikely   None Very low  
Rohn et al14 Cohort  Seriouse Seriousa Not Serious  Not Serious Unlikely   None Very low 
a Made an indirect correlation between oxytocin use and emergency CS rates.  
bLacked sufficient explanation for their findings, which include a significant increase in oxytocin augmentation in patients without dystocia and an increase in       
emergency CS, but with no change in the rate of dystocia as an indication for emergency CS post-guideline.  
cThe study permitted the range of low and high dose oxytocin regimen accepted by ACOG. 
dOnly 100 charts were reviewed each for the pre- and post- guideline groups, but then the protocol was employed across an entire health care system.  
eInadequate control of variables led to confounding: a new low-dose oxytocin regimen and a new checklist-based protocol. Also, the study did not exclude women with a 
history of CS which created a significant population difference from the other studies. 
